Cancer Epidemiology Biomarkers & Prevention, Vol 5, Issue 4 293-296, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Detection of tyrosinase mRNA from the blood of melanoma patients

GL Stevens, WD Scheer and EA Levine
Section of Molecular Pathology, Louisiana State University Medical Center, New Orleans 70112, USA.

Surgical therapy for localized melanoma is highly successful. However, if melanoma spreads beyond its primary site, the results of treatment are poor. Therefore, early detection of circulating melanoma cells in the blood may be important. Currently, circulating melanoma cells are undetectable. Tyrosinase is an enzyme in the melanin synthetic pathway the expression of which is only found in melanin-producing cells. Because melanocytes are not normally found in the peripheral blood, we hypothesize that melanoma cells circulating in the peripheral blood could be detected by amplifying the tyrosinase mRNA using the reverse transcription-PCR (RT-PCR). The purpose of this study was to determine the sensitivity of a RT-PCR-based assay for tyrosinase mRNA from peripheral blood and evaluate correlations with tumor status in melanoma patients. RNA was isolated from the peripheral blood or tissue culture cells, and cDNA was prepared. DNA was amplified using RT-PCR with nested primers for tyrosinase and beta(2)-microglobulin. Serial dilution experiments using cells from the SK-MEL-28 cell line were performed in culture media and in whole blood. Twelve patients with melanoma, 10 healthy controls, and 15 patients with nonmelanoma malignancies were tested for tyrosinase expression in peripheral blood. The sensitivity of this assay was determined to be as low as 1 melanoma cell in 5 ml of whole blood. No tyrosinase was found in healthy subjects or other cancer control patients. Tyrosinase mRNA was detected in the blood of five melanoma patients (one stage II, two stage III, and two stage IV). Three of these tyrosinase-positive patients had biopsy-proven evidence of melanoma, whereas the other two had no clinical evidence of malignant disease after surgical resection. The remaining seven melanoma patients had no evidence of disease and tested negative for tyrosinase mRNA. This study suggests that a RT-PCR-based assay for the detection of tyrosinase mRNA in peripheral blood is feasible. Moreover, the presence of tyrosinase mRNA in the blood seems to correlate with the stage of melanoma. Further study and follow-up are needed to clarify the role of tyrosinase mRNA as a tumor marker for malignant melanoma.

This article has been cited by other articles:

				J. P. Dutcher The Prognostic Role of Detection of Circulating Melanoma Cells in the Blood J. Clin. Oncol., March 1, 2003; 21(5): 757 - 759. [Full Text] [PDF]

				G. Palmieri, P. A. Ascierto, F. Perrone, S. M.R. Satriano, A. Ottaiano, A. Daponte, M. Napolitano, C. Caraco, N. Mozzillo, M. T. Melucci, et al. Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction J. Clin. Oncol., March 1, 2003; 21(5): 767 - 773. [Abstract] [Full Text] [PDF]

				U. Reinhold, C. Berkin, A.-K. Bosserhoff, A. Deutschmann, C. Garbe, R. Glaser, R. Hein, G. Krahn, R. U. Peter, G. Rappl, et al. Interlaboratory Evaluation of a New Reverse Transcriptase Polymerase Chain Reaction-Based Enzyme-Linked Immunosorbent Assay for the Detection of Circulating Melanoma Cells: A Multicenter Study of the Dermatologic Cooperative Oncology Group J. Clin. Oncol., March 15, 2001; 19(6): 1723 - 1727. [Abstract] [Full Text] [PDF]

				H. Tsao, U. Nadiminti, A. J. Sober, and M. Bigby A Meta-analysis of Reverse Transcriptase-Polymerase Chain Reaction for Tyrosinase mRNA as a Marker for Circulating Tumor Cells in Cutaneous Melanoma Arch Dermatol, March 1, 2001; 137(3): 325 - 330. [Abstract] [Full Text] [PDF]

				K S Clarkson, I C Sturdgess, and A J Molyneux The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A) J. Clin. Pathol., March 1, 2001; 54(3): 196 - 200. [Abstract] [Full Text] [PDF]

				G. Palmieri, M. Strazzullo, P. A. Ascierto, S. M.R. Satriano, A. Daponte, and G. Castello Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression J. Clin. Oncol., January 1, 1999; 17(1): 304 - 304. [Abstract] [Full Text] [PDF]

				R. Halaban, E. Cheng, Y. Zhang, G. Moellmann, D. Hanlon, M. Michalak, V. Setaluri, and D. N. Hebert Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells PNAS, June 10, 1997; 94(12): 6210 - 6215. [Abstract] [Full Text] [PDF]